pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

AstraZeneca opens 570,000-sq-ft R&D campus in Cambridge, targeting 2,000 staff

Oct 6, 2026·read at Endpoints ↗Positive

AstraZeneca inaugurated a new research and development building in Cambridge, Massachusetts on Monday.

The facility spans 570,000 square feet and is expected to house about 2,000 employees once fully operational.

The company said the investment reflects its policy of allocating roughly a quarter of annual revenue to R&D.

Officials including senior vice presidents, Massachusetts Governor Maura Healey and CEO Pascal Soriot attended the opening.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “AstraZeneca heralds new R&D facility in that ‘other’ Cambridge”

read at Endpoints ↗
102 words · retrieved 35m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA4BARR

related stories

  • 11h agoAstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D centerFierce Biotech
  • Sep 8AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDFierce Biotech
  • Aug 27AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisBioSpace
  • May 8Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive
  • May 8Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive